BACKGROUND: Recently, we reported a reduced retinal contrast gain in unmedicated and medicated patients with major depression. AIMS: To analyse whether the contrast gain normalises after successful antidepressive therapy by recording the pattern electroretinogram (PERG) in healthy controls and patients with depression before and after antidepressive therapy. METHOD: Fourteen patients diagnosed with major depression were repeatedly scanned and the results compared with that from 40 matched controls. RESULTS: The retinal contrast gain was lower at baseline in patients with depression, was normalised with remission and correlated with the severity of depression. Patients who did not achieve remission retained significantly lower contrast gain at follow-up. CONCLUSIONS: The study provides evidence for a state-dependent modulation of retinal contrast gain in patients with major depression. Reduced contrast gain normalised after therapy. A PERG-based contrast gain could serve as a state marker of depression.
BACKGROUND: Recently, we reported a reduced retinal contrast gain in unmedicated and medicated patients with major depression. AIMS: To analyse whether the contrast gain normalises after successful antidepressive therapy by recording the pattern electroretinogram (PERG) in healthy controls and patients with depression before and after antidepressive therapy. METHOD: Fourteen patients diagnosed with major depression were repeatedly scanned and the results compared with that from 40 matched controls. RESULTS: The retinal contrast gain was lower at baseline in patients with depression, was normalised with remission and correlated with the severity of depression. Patients who did not achieve remission retained significantly lower contrast gain at follow-up. CONCLUSIONS: The study provides evidence for a state-dependent modulation of retinal contrast gain in patients with major depression. Reduced contrast gain normalised after therapy. A PERG-based contrast gain could serve as a state marker of depression.
Authors: Jana Zweerings; Mikhail Zvyagintsev; Bruce I Turetsky; Martin Klasen; Andrea A König; Erik Roecher; Arnim J Gaebler; Klaus Mathiak Journal: Hum Brain Mapp Date: 2019-05-12 Impact factor: 5.038
Authors: Emanuel Bubl; Michael Dörr; Alexandra Philipsen; Dieter Ebert; Michael Bach; Ludger Tebartz van Elst Journal: PLoS One Date: 2013-05-02 Impact factor: 3.240
Authors: Ludger Tebartz van Elst; Michael Bach; Julia Blessing; Andreas Riedel; Emanuel Bubl Journal: Front Hum Neurosci Date: 2015-08-26 Impact factor: 3.169
Authors: Emanuel Bubl; Michael Dörr; Andreas Riedel; Dieter Ebert; Alexandra Philipsen; Michael Bach; Ludger Tebartz van Elst Journal: PLoS One Date: 2015-02-18 Impact factor: 3.240
Authors: M Moreno-Ortega; J Prudic; S Rowny; G H Patel; A Kangarlu; S Lee; J Grinband; T Palomo; T Perera; M F Glasser; D C Javitt Journal: Sci Rep Date: 2019-03-25 Impact factor: 4.379
Authors: Eve Cosker; Marie Moulard; Samuel Schmitt; Karine Angioi-Duprez; Cédric Baumann; Vincent Laprévote; Raymund Schwan; Thomas Schwitzer Journal: BMJ Open Date: 2021-07-09 Impact factor: 2.692